This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Street Elite Get Early Crack at Arena Study

BOSTON ( TheStreet) -- On Tuesday afternoon, SummerStreet Research Partners, a healthcare research shop, sent emails informing its institutional investor clients about an important study and related editorial concerning Arena Pharmaceuticals (ARNA - Get Report) that were published in this week's New England Journal of Medicine.

Here, in full, is the text of the email sent Tuesday to investor clients about Arena and the NEJM by SummerStreet Research:

"ARNA (BUY), The BLOOM trial is published today in the NEJM with an editorial. The editorial points out that lorcaserin has slightly less than or equal efficacy to Orlistat and slightly less efficacy than Meridia (sibutramine). However the justification of approval for lorcaserin is that its safety profile appears to be better than that of Xenical (orlistat) or sibutramine. In addition, lorcaserin appears to result in improvement of all surrogate measures of diabetes and cardiovascular risk: the effect is small however clinically relevant. This is important since sibutramine did not and subsequently went on to demonstrate negative cardiovascular outcome in the SCOUT trial. The SCOUT trial results will be presented tomorrow at the International Obestity conference in Stockholm. The author of the editorial suggests that lorcaserin will probably be used in combination, perhaps with GLP-1s (prior to phentermine). Overall we consider the publication a positive for the shares and it bodes well for the September 16th advisory panel meeting (bolsters the Eisai deal – safety first novel agent)."

Later Tuesday night, J.P. Morgan biotech analyst Geoff Meacham also sent an email to his investor clients, telling them about an HIV study likewise published in this week's NEJM that has implications for Gilead Sciences (GILD - Get Report).

Normally, these emails wouldn't raise an eyebrow. Research analysts are just doing their jobs when they make sure clients stay abreast of all the latest medical information that can affect stock prices.

Yet, if I had published stories Tuesday similarly informing readers about studies related to Arena and Gilead published in this week's NEJM, the journal editors would have screamed foul. And they may be doing exactly that as they read this column.

The NEJM's media embargo policy forbids journalists from publishing stories about medical studies in the current issue of the NEJM until Wednesday nights, one day prior to the journal's official Thursday publication date. The NEJM, like many other medical and scientific journals, places embargoes on studies to give journalists time to interview experts and prepare stories.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARNA $4.34 0.12%
GILD $101.09 0.02%
OREX $7.25 0.00%
VVUS $2.49 0.00%
AAPL $124.24 0.00%

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs